UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Second Amended and Restated
SCHEDULE 13D

Under the Securities Exchange Act of 1934




Clene Inc.
(Name of Issuer)

Common Stock, $0.0001 par value
(Title of Class of Securities)


185634102
(CUSIP Number)

David J. Matlin
61 Cedar Pt Lane
Sag Harbor, NY 11963
(917) 841-2666
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

November 2, 2022
(Date of Event which Requires Filing of this Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.




1
NAME OF REPORTING PERSON
David J. Matlin
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 
(a) 
(b) ☐
3
SEC USE ONLY
 
4
SOURCE OF FUNDS
PF
 
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
6
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
 
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
5,454,362 (1)
 
8
SHARED VOTING POWER
150,000
 
9
SOLE DISPOSITIVE POWER
5,454,362 (1)
 
10
SHARED DISPOSITIVE POWER
150,000
 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,604,362 (1)
 
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.6% (2)
 
14
TYPE OF REPORTING PERSON
IN
 

(1)
Includes 160,678 shares of Common Stock issuable upon the exercise of options held by David J. Matlin, which are currently exercisable or will be exercisable within 60 days.
(2)
Based on a total of 73,980,688 shares of Common Stock, comprised of (i) 73,820,010 shares of Common Stock of the Issuer outstanding as of November 2, 2022, as disclosed on the Issuer’s Form 10-Q filed with the SEC on November 7, 2022, and (ii) 160,678 shares of Common Stock issuable upon the exercise of options held by David J. Matlin, which are currently exercisable or will be exercisable within 60 days.


Explanatory Note

This Second Amended and Restated Schedule 13D (this “Second Amended and Restated Schedule 13D”) amends and restates the Amended and Restated Schedule 13D that was filed on February 17, 2023 (the “Prior Amended Schedule 13D”), which itself amended and restated the Schedule 13D that was originally filed on February 6, 2023 (the “Original Schedule 13D”), and is being filed to update and correct the beneficial ownership information of the Reporting Person on the cover page and in Items 5(a) and 5(b) to reflect an additional 2,500 shares of the Company’s Common Stock issuable upon exercise of options that are not currently exercisable but will be exercisable within 60 days of the date of both this filing and the filing date of the Prior Amended Schedule 13D.  Such shares were not previously reported on the Original Schedule 13D as they would not have been issuable within 60 days of the Original Schedule 13D’s filing date of February 6, 2023. The Original Schedule 13D and the Prior Amended Schedule 13D were inadvertently filed only under the Company’s Central Index Key (CIK) Number (and not under the Reporting Person’s CIK) on February 6, 2023 and February 17, 2023, respectively.

Item 1.
Security and Issuer
This Second Amended and Restated Schedule 13D amends and restates the Prior Amended Schedule 13D, which itself amended and restated the Original Schedule 13D, and relates to the common stock, $0.0001 par value (“Common Stock”), of Clene Inc. (the “Company”).  The address of the principal executive offices of the Company is 6550 South Millrock Drive, Suite G50, Salt Lake City, Utah 84121.
Item 2.
Identity and Background

 
 (a)
 This Second Amended and Restated Schedule 13D is being filed by David J. Matlin (the “Reporting Person”).

 
 (b)
 The address of the Reporting Person is 61 Cedar Pt Lane, Sag Harbor, New York 11963.

 
 (c)
 The principal occupation of the Reporting Person is serving as investor for his personal assets.

 
 (d)-(e)
 During the last five years, the Reporting Person (i) has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) and (ii) has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceedings was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect at such laws.

 
 (f)
 The Reporting Person is a citizen of the United States.

Item 3.
Source and Amount of Funds or Other Consideration

The total amount of funds used for the purchase of Common Stock by the Reporting Person was $13.2 million. All of the shares of Common Stock beneficially owned by the Reporting Person, other than shares of Common Stock issuable upon the exercise of options, were paid for using personal funds, and the options held by the Reporting Person to purchase shares of Common Stock were granted to the Reporting Person under the Clene Inc. 2020 Stock Plan.
Additional detailed information regarding the securities of the Company acquired by the Reporting Person since November 2, 2022 (which are included in the total figures included elsewhere herein) follows:

On November 2, 2022, the Reporting Person used personal funds to purchase 2,871,287 shares of Common Stock for approximately $2.9 million.

On November 3, 2022, the Reporting Person was granted options to purchase 21,476 shares of Common Stock under the Clene Inc. 2020 Stock Plan, which vested immediately upon grant and have an exercise price of $1.19 per share. These options are beneficially owned by the Reporting Person, as they are currently exercisable.

On February 2, 2023, the Reporting Person was granted options to purchase 15,894 shares of Common Stock under the Clene Inc. 2020 Stock Plan, which vested immediately upon grant and have an exercise price of $1.62 per share. These options are beneficially owned by the Reporting Person, as they are currently exercisable.

Item 4.
Purpose of Transaction

The Reporting Person purchased the Common Stock based on the belief that such securities, at current market prices, represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities, and the availability of Common Stock at desirable prices, the Reporting Person may endeavor to increase his position in the Company through, among other things, the purchase of Common Stock in open market or private transactions on such terms and at such times as the Reporting Person deems advisable.

The Reporting Person intends to review his investment in the Company on a continuing basis taking into consideration various factors, including the Company’s business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for shares of Common Stock and the Company, in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Person will take such actions in the future as the Reporting Person may deem appropriate in light of the circumstances existing from time to time, which may include further acquisitions of shares of Common Stock of the Company or disposal of some or all of the shares of Common Stock of the Company owned by the Reporting Person or otherwise acquired by the Reporting Person, either in the open market or in privately negotiated transactions.

Pursuant to the Reporting Person’s continued service as Chairman of the Board of Directors of the Company, the Reporting Person may receive future equity awards from the Company in accordance with the applicable equity plans, as may be in effect from time to time.

As Chairman of the Board of Directors of the Company, the Reporting Person is involved in the oversight and management of the Company and setting policy for the Company. The Reporting Person participates with the Board of Directors of the Company in the consideration of, and taking action on, significant corporate events and opportunities involving the Company. As a result, from time to time the Reporting Person may consider proposals that relate to or would result in the matters listed in Items 4(a)-(j) of Schedule 13D.

Except as set forth in this Second Amended and Restated Schedule 13D, the Reporting Person has not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Company or the disposition of securities of the Company, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Company or any of its subsidiaries, (c) a sale or transfer of a material amount of the assets of the Company or any of its subsidiaries, (d) any change in the present Board of Directors or management of the Company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board, (e) any material change in the Company’s capitalization or dividend policy of the Company, (f) any other material change in the Company’s business or corporate structure, (g) any change in the Company’s charter or bylaws or other instrument corresponding thereto or other action which may impede the acquisition of control of the Company by any person, (h) causing a class of the Company’s securities to be deregistered or delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association, (i) a class of equity securities of the Company becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934, as amended (the "Act") or (j) any action similar to any of those enumerated above.

Item 5.
Interest in Securities of the Company

(a)
 The Reporting Person beneficially owns 5,604,362 shares of Common Stock, which represents 7.6% of the outstanding shares of Common Stock (based on a total of 73,980,688 shares of Common Stock, comprised of (i) 73,820,010 shares of Common Stock of the Company outstanding as of November 2, 2022, as disclosed on the Company’s Form 10-Q filed with the SEC on November 7, 2022, and (ii) 160,678 shares of Common Stock of the Company issuable upon the exercise of options held by the Reporting Person, which are currently exercisable or will be exercisable within 60 days).
(b)
The Reporting Person has sole voting and dispositive power over 5,454,362 shares of Common Stock, which includes 160,678 shares of Common Stock issuable upon the exercise of options held by the Reporting Person, which are currently exercisable or will be exercisable within 60 days. The Reporting Person has shared voting and dispositive power over 150,000 shares of Common Stock that are held by the Matlin Family Trust 2020, of which the Reporting Person is the trustee.
Except for the grant of options to purchase 15,894 shares of Common Stock under the Clene Inc. 2020 Stock Plan (as described in Item 3 of this Second Amended and Restated Schedule 13D), there have been no transactions in the Company’s Common Stock effected by the Reporting Person during the last 60 days.
All transactions in the Company’s Common Stock effected by the Reporting Person between November 2, 2022 and the date of this filing are described in Item 3 above.
There were no transactions in the Company’s Common Stock effected by the Reporting Person during the 60 days preceding November 2, 2022.
(c)
To the best knowledge of the Reporting Person, no one other than the Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock beneficially owned by the Reporting Person.
(d)
Not applicable.

 Item 6.
 Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Company
To the knowledge of the Reporting Person, except for those matters described in this Second Amended and Restated Schedule 13D, there is no contract, arrangement, understanding or relationship (legal or otherwise) between the Reporting Person and any other person with respect to securities of the Company.
 Item 7.
 Material to be Filed as Exhibits
None.
[Signatures follow on the next page.]


SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 21, 2023

DAVID J. MATLIN


By: /s/ David J. Matlin                         
       David J. Matlin